Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: FDA Approves Argenx’s VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Chronic Inflammatory Demyelinating Polyneuropathy

Jun 21, 2024

On 21 June 2025, Argenx announced that the FDA approved a new indication of its VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for chronic inflammatory demyelinating polyneuropathy (CIDP).  

VYVGART Hytrulo is approved for CIDP, administered as a subcutaneous injection once weekly lasting 30 to 90 seconds. It is notable as the only neonatal Fc receptor (FcRn) blocker approved for treating CIDP.